← Leaderboards
Jon Oscherwitz
Veterans Health Administration
$527,973
Attributed
$1,055,946
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $273.7K · FY2014–25$500K$375K$250K$125K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,055,946 · 2
VA$0 · 1
By mechanism
R41$1,055,946 · 2
I01$0 · 1
Top collaborators
- David C Whitacre4 shared
Others in their field
Top investigators on “Toxin”
- Jacqueline Moline · Icahn School Of Medicine At Mount Sinai$75,762,106
- Rosalind J Wright · Icahn School Of Medicine At Mount Sinai$75,392,927
- Alessandro Sette · La Jolla Institute For Immunology$39,651,711
- Milan Tomic · Xoma Corporation$38,826,613
- Jon Mirsalis · Sri International$38,701,962
- Robert H Vonderheide · University Of Pennsylvania$33,448,494
Research focus
ToxinAntigensVirus-Like ParticleAdjuvantAerosolsBacillus AnthracisNeutralizing AntibodyVaccinesEpitopesImmune SeraImmunogenicOryctolagus CuniculusAntibodiesImmunityHumoral ImmunitiesDesignImmunizationHospitalsCommunitiesGrowthEvaluationHost DefenseBacterial EndocarditisBacteria
Grant awards (10)
A multivalent vaccine for Staphylococcus aureus$0
I01 · FY2025 · VA · contact PI
A multivalent vaccine for Staphylococcus aureus$0
I01 · FY2024 · VA · contact PI
A multivalent vaccine for Staphylococcus aureus$0
I01 · FY2023 · VA · contact PI
A multivalent vaccine for Staphylococcus aureus$0
I01 · FY2022 · VA · contact PI
A multivalent vaccine for Staphylococcus aureus$0
I01 · FY2021 · VA · contact PI
A multivalent vaccine for Staphylococcus aureus$0
I01 · FY2020 · VA · contact PI
An epitope-focused nanoparticle vaccine for MRSA and biodefense$272,381
R41 · FY2017 · AI · contact PI
An epitope-focused nanoparticle vaccine for MRSA and biodefense$273,748
R41 · FY2016 · AI · contact PI
A molecularly targeted pre- and post-exposure vaccine for anthrax$249,612
R41 · FY2015 · AI · contact PI
A molecularly targeted pre- and post-exposure vaccine for anthrax$260,205
R41 · FY2014 · AI · contact PI